Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname-Reference-Cited by-同舟云学术

Reduced Mortality among COVID-19 ICU Patients after Treatment with HemoClear Convalescent Plasma in Suriname

Published:2023-04-25 Issue:2 Volume:14 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Bihariesingh-Sanchit R.¹²^ORCID,Bansie R.³,Ramdhani N.¹,Mangroo R.³,Bustamente D.¹,Diaz E.²,Fung A Foek C.¹,Thakoer I.⁴,Vreden S.³,Choudhry Z.⁵,van ‘t Wout A. B.⁶⁷^ORCID,Diavatopoulos D. A.⁸⁹,Nierich A. P.¹⁰¹¹

Affiliation:

1. Department of Anesthesiology, Academic Hospital Paramaribo, Paramaribo, Suriname

2. Department of Intensive Care, Academic Hospital Paramaribo, Paramaribo, Suriname

3. Department of Internal Medicine, Academic Hospital Paramaribo, Paramaribo, Suriname

4. Department of Radiology, Academic Hospital Paramaribo, Paramaribo, Suriname

5. Department of Nephrology and Therapeutic Apheresis, Horacio Oduber Hospital, Oranjestad, Aruba

6. AlphaBiomics Limited, London, United Kingdom

7. van ‘t Wout Pharma Consulting, Amsterdam, The Netherlands

8. Section Paediatric Infectious Diseases, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

9. Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands

10. Departments of Anesthesiology and Intensive Care, Isala, Zwolle, The Netherlands

11. HemoClear BV, Zwolle, The Netherlands

Abstract

This study compares mortality and other endpoints between intensive care unit COVID-19 patients treated with convalescent plasma plus standard of care (CCP), and a control group of patients hospitalized in the same medical ICU facility treated with standard of care alone (SOC) in a low- and middle-income country (LMIC) setting using bedside donor whole blood separation by gravity (HemoClear) to produce the CCP. It demonstrates a significant 65% survival improvement in HemoClear-produced CCP recipients (HR, 0.35; 95% CI, 0.19 to 0.66; P = 0.001).

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.03379-22

Reference42 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin

2. A new coronavirus associated with human respiratory disease in China

3. Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

4. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

5. THE USE OF CONVALESCENT HUMAN SERUM IN INFLUENZA PNEUMONIA—A PRELIMINARY REPORT

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HemoClear: A Practical and Cost-Effective Alternative to Conventional Convalescent Plasma Retrieval Methods;Current Topics in Microbiology and Immunology;2024

2. The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review;Life;2023-12-11

3. Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy;Expert Review of Respiratory Medicine;2023-05-02